Infection by the human immunodeficiency virus (HIV) is increasing among women. After the advent of highly active antiretroviral therapy (HAART), a decrease occurred in the mortality rate, which now seems to have stabilized. One of the consequences of this current situation is that more and more HIV-infected women are now reaching menopause. Therefore, factors often investigated in seronegative women need to be evaluated in middle-aged, HIV-positive women. In midlife, HIV-positive women will experience the onset of menopause, while concomitantly they may also be affected by metabolic complications related to the HIV infection and to HAART. This literature review was therefore carried out to identify studies dealing with conditions related to middle-aged women with HIV with the aim of providing data on age at menopause, menopausal symptoms, reproductive hormones, cognitive function, bone mineral density, cardiovascular disease, and lipid and glucose metabolism in middle-aged women with HIV and discussing these issues. Some of these factors may be aggravated by the HIV infection and by HAART. The prevention and treatment of these conditions in middle-aged, HIV-positive women are discussed in the light of current knowledge. Copyright © 2009 The North American Menopause Society.161199213(2007) AIDS epidemic update, , http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf, Geneva: UNAIDSDecember, Available at:, Accessed December 10, 2007Ghosh, J., Kalipeni, E., Women in Chinsapo, Malawi: Vulnerability and risk to HIV/AIDS (2005) SAHARA J, 2, pp. 320-332Lin, K., McElmurry, B.J., Christiansen, C., Women and HIV/AIDS in China: Gender and vulnerability (2007) Health Care Women Int, 28, pp. 680-699Sormanti, M., Shibusawa, T., Predictors of condom use and HIV testing among midlife and older women seeking medical services (2007) J Aging Health, 19, pp. 705-719HIV/AIDS Fact Sheet HIV/AIDS among women, , http://www.cdc.gov/hiv/resources/factsheets/PDF/women.pdf, Available at:, Accessed December 16, 2007(2006) Epidemiological Bulletin STDs/AIDS-1st to the 26th epidemiological weeks, , http://www.aids.gov.br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B6B12D137-92DF-4CF5-A35A-482AED64CBC0%7D/BOLETIM2006internet.pdf, Brazilian Ministry of Health, Available at:, Accessed December 20, 2007Schechter, M., Treatment at scale in Brazil: A physician's perspective (2007) AIDS, 21 (SUPPL. 4), pp. S31-S35Hacker, M.A., Petersen, M.L., Enriquez, M., Bastos, F.I., Highly active antiretroviral therapy in Brazil: The challenge of universal access in a context of social inequality (2004) Rev Panam Salud Publica, 16, pp. 78-83Clark, R.A., Cohn, S.E., Jarek, C., Perimenopausal symptomatology among HIV-infected women at least 40 years of age (2000) J Acquir Immune Defic Syndr, 23, pp. 99-100Fantry, L.E., Zhan, M., Taylor, G.H., Sill, A.M., Flaws, J.A., Age of menopause and menopausal symptoms in HIV-infected women (2005) AIDS Patient Care STDS, 19, pp. 703-711Ferreira, C.E., Pinto-Neto, A.M., Conde, D.M., Costa-Paiva, L., Morais, S.S., Magalhaes, J., Menopause symptoms in women infected with HIV: Prevalence and associated factors (2007) Gynecol Endocrinol, 23, pp. 198-205Schoenbaum, E.E., Hartel, D., Lo, Y., HIV infection, drug use, and onset of natural menopause (2005) Clin Infect Dis, 41, pp. 1517-1524Cejtin, H.E., Kim, S., Taylor, R.N., Menopause in women in the Women's Interagency HIV Study (WIHS) (2004) Bangkok: XV International AIDS Conference, , http://gateway.nlm.nih.gov/MeetingAbstracts/102284419.html, abstract WePeD6504, Available at:, Accessed December 1, 2007Miller, S.A., Santoro, N., Lo, Y., Menopause symptoms in HIV-infected and drug-using women (2005) Menopause, 12, pp. 348-356Santoro, N., Arnsten, J.H., Buono, D., Howard, A.A., Schoenbaum, E.E., Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women (2005) J Womens Health (Larchmt), 14, pp. 898-905Cofrancesco Jr, J., Shah, N., Ghanem, K.G., The effects of illicit drug use and HIV infection on sex hormone levels in women (2006) Gynecol Endocrinol, 22, pp. 244-251Santoro, N., Lo, Y., Moskaleva, G., Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women (2007) Menopause, 14, pp. 859-865Richardson, J.L., Martin, E.M., Jimenez, N., Neuropsychological functioning in a cohort of HIV infected women: Importance of antiretroviral therapy (2002) J Int Neuropsychol Soc, 8, pp. 781-793Dolan, S., Montagno, A., Wilkie, S., Neurocognitive function in HIV-infected patients with low weight and weight loss (2003) J Acquir Immune Defic Syndr, 34, pp. 155-164Teichmann, J., Stephan, E., Lange, U., Osteopenia in HIV-infected women prior to highly active antiretroviral therapy (2003) J Infect, 46, pp. 221-227Dolan, S.E., Huang, J.S., Killilea, K.M., Sullivan, M.P., Aliabadi, N., Grinspoon, S., Reduced bone density in HIV-infected women (2004) AIDS, 18, pp. 475-483Yin, M., Dobkin, J., Brudney, K., Bone mass and mineral metabolism in HIV+ postmenopausal women (2005) Osteoporos Int, 16, pp. 1345-1352Arnsten, J.H., Freeman, R., Howard, A.A., Floris-Moore, M., Santoro, N., Schoenbaum, E.E., HIV infection and bone mineral density in middle-aged women (2006) Clin Infect Dis, 42, pp. 1014-1020Dolan, S.E., Kanter, J.R., Grinspoon, S., Longitudinal analysis of bone density in human immunodeficiency virus-infected women (2006) J Clin Endocrinol Metab, 91, pp. 2938-2945Dolan, S.E., Hadigan, C., Killilea, K.M., Increased cardiovascular disease risk indices in HIV-infected women (2005) J Acquir Immune Defic Syndr, 39, pp. 44-54Floris-Moore, M., Howard, A.A., Lo, Y., Arnsten, J.H., Santoro, N., Schoenbaum, E.E., Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women (2006) HIV Med, 7, pp. 421-430Rimland, D., Guest, J.L., Hernandez-Ramos, I., Del Rio, C., Le, N.A., Brown, W.V., Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol (2006) J Acquir Immune Defic Syndr, 42, pp. 307-313Anastos, K., Lu, D., Shi, Q., Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens (2007) J Acquir Immune Defic Syndr, 45, pp. 34-42Justman, J.E., Benning, L., Danoff, A., Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women (2003) J Acquir Immune Defic Syndr, 32, pp. 298-302Howard, A.A., Floris-Moore, M., Arnsten, J.H., Disorders of glucose metabolism among HIV-infected women (2005) Clin Infect Dis, 40, pp. 1492-1499Danoff, A., Shi, Q., Justman, J., Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women (2005) J Acquir Immune Defic Syndr, 39, pp. 55-62Tien, P.C., Schneider, M.F., Cole, S.R., Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study (2007) AIDS, 21, pp. 1739-1745HIV/AIDS Surveillance Report, 2005, , http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2005report/pdf/2005SurveillanceReport.pdf, Revised June 2007. Available at:, Accessed December 20, 2007(2005) Epidemiological Bulletin STDs/AIDS-1st to the 26th epidemiological weeks, , http://www.aids.gov.br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7BED005A42-14BE-4F7E-98A7-E6AD7CD9A76D%7D/BOLETIMpdf, Brazilian Ministry of Health, Available at:, Accessed December 20, 2007Epidemiology of HIV/AIDS in Chile. December 2003 (2005) Rev Chilena Infectol, 22, pp. 169-202. , Comision Nacional de SIDA-CONASIDAEpidemiology of HIV/AIDS-United States, 1981-2005 (2006) MMWR Morb Mortal Wkly Rep, 55, pp. 589-592. , Centers for Disease Control and Prevention CDCHIV/AIDS Surveillance in Women, , http://www.cdc.gov/hiv/topics/surveillance/resources/slides/women/slides/Women.pdf, Revised June 2007. Available at:, Accessed December 18, 2007Binson, D., Pollack, L., Catania, J.A., AIDS-related risk behaviors and safer sex practices of women in midlife and older in the United States: 1990 to 1992 (1997) Health Care Women Int, 18, pp. 343-354Ory, M.G., Mack, K.A., Middle-aged and older people with AIDS: Trends in national surveillance rates, transmission routes, and risk factors (1998) Res Aging, 20, pp. 653-664Akers, A., Bernstein, L., Henderson, S., Doyle, J., Corbie-Smith, G., Factors associated with lack of interest in HIV testing in older at-risk women (2007) J Womens Health (Larchmt), 16, pp. 842-858Henderson, S.J., Bernstein, L.B., St. George, D.M., Doyle, J.P., Paranjape, A.S., Corbie-Smith, G., Older women and HIV: How much do they know and where are they getting their information? (2004) J Am Geriatr Soc, 52, pp. 1549-1553Winningham, A., Corwin, S., Moore, C., Richter, D., Sargent, R., Gore-Felton, C., The changing age of HIV: Sexual risk among older African American women living in rural communities (2004) Prev Med, 39, pp. 809-814Gott, M., Hinchliff, S., Barriers to seeking treatment for sexual problems in primary care: A qualitative study with older people (2003) Fam Pract, 20, pp. 690-695Paranjape, A., Bernstein, L., St. George, D.M., Doyle, J., Henderson, S., Corbie-Smith, G., Effect of relationship factors on safer sex decisions in older inner-city women (2006) J Womens Health (Larchmt), 15, pp. 90-97Gold, E.B., Bromberger, J., Crawford, S., Factors associated with age at natural menopause in a multiethnic sample of midlife women (2001) Am J Epidemiol, 153, pp. 865-874Mondul, A.M., Rodriguez, C., Jacobs, E.J., Calle, E.E., Age at natural menopause and cause-specific mortality (2005) Am J Epidemiol, 162, pp. 1089-1097Parazzini, F., Progetto Menopause Italia Study Group. Determinants of age at menopause in women attending menopause clinics in Italy (2007) Maturitas, 56, pp. 280-287Castelo-Branco, C., Blümel, J.E., Chedraui, P., Age at menopause in Latin America (2006) Menopause, 13, pp. 706-712Snieder, H., MacGregor, A.J., Spector, T.D., Genes control the cessation of a woman's reproductive life: A twin study of hysterectomy and age at menopause (1998) J Clin Endocrinol Metab, 83, pp. 1875-1880Pedro, A.O., Pinto-Neto, A.M., Paiva, L.H., Osis, M.J., Hardy, E., Age at natural menopause among Brazilian women: Results from a population-based survey (2003) Cad Saude Publica, 19, pp. 17-25Fallahzadeh, H., Age at natural menopause in Yazd, Islamic Republic of Iran (2007) Menopause, 14, pp. 900-904Cejtin, H.E., Kalinowski, A., Bacchetti, P., Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction (2006) Obstet Gynecol, 108, pp. 1423-1431Soules, M.R., Sherman, S., Parrott, E., Executive summary: Stages of Reproductive Aging Workshop (STRAW) (2001) Fertil Steril, 76, pp. 874-878van Der Voort, D.J., van Der Weijer, P.H., Barentsen, R., Early menopause: Increased fracture risk at older age (2003) Osteoporos Int, 14, pp. 525-530van der Klift, M., de Laet, C.E., McCloskey, E.V., Risk factors for incident vertebral fractures in men and women: The Rotterdam Study (2004) J Bone Miner Res, 19, pp. 1172-1180Hu, F.B., Grodstein, F., Hennekens, C.H., Age at natural menopause and risk of cardiovascular disease (1999) Arch Intern Med, 159, pp. 1061-1066Ossewaarde, M.E., Bots, M.L., Verbeek, A.L., Age at menopause, cause-specific mortality and total life expectancy (2005) Epidemiology, 16, pp. 556-562Atsma, F., Bartelink, M.L., Grobbee, D.E., van der Schouw, Y.T., Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis (2006) Menopause, 13, pp. 265-279Conde, D.M., Pinto-Neto, A.M., Costa-Paiva, L., Age at menopause of HIV-infected women: A review (2008) Gynecol Endocrinol, 24, pp. 84-86Conde, D.M., Pinto-Neto, A.M., Santos-Sa, D., Costa-Paiva, L., Martinez, E.Z., Factors associated with quality of life in a cohort of postmenopausal women (2006) Gynecol Endocrinol, 22, pp. 441-446Gold, E.B., Sternfeld, B., Kelsey, J.L., Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age (2000) Am J Epidemiol, 152, pp. 463-473Fuh, J.L., Wang, S.J., Lee, S.J., Lu, S.R., Juang, K.D., Quality of life and menopausal transition for middle-aged women on Kinmen Island (2003) Qual Life Res, 12, pp. 53-61Greene, J.G., Constructing a standard climacteric scale (1998) Maturitas, 29, pp. 25-31Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society (2007) Menopause, 14, pp. 168-182. , North American Menopause SocietyChen, L.F., Hoy, J., Lewin, S.R., Ten years of highly active antiretroviral therapy for HIV infection (2007) Med J Aust, 186, pp. 146-151Walubo, A., The role of cytochrome P450 in antiretroviral drug interactions (2007) Expert Opin Drug Metab Toxicol, 3, pp. 583-598Stearns, V., Beebe, K.L., Iyengar, M., Dube, E., Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial (2003) JAMA, 289, pp. 2827-2834Gordon, P.R., Kerwin, J.P., Boesen, K.G., Senf, J., Sertraline to treat hot flashes: A randomized controlled, double-blind, crossover trial in a general population (2006) Menopause, 13, pp. 568-575Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial (2000) Lancet, 356, pp. 2059-2063Evans, M.L., Pritts, E., Vittinghoff, E., McClish, K., Morgan, K.S., Jaffe, R.B., Management of postmenopausal hot flushes with venlafaxine hydrochloride: A randomized, controlled trial (2005) Obstet Gynecol, 105, pp. 161-166Pandya, K.J., Raubertas, R.F., Flynn, P.J., Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study (2000) Ann Intern Med, 132, pp. 788-793Pandya, K.J., Morrow, G.R., Roscoe, J.A., Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial (2005) Lancet, 366, pp. 818-824Nelson, H.D., Vesco, K.K., Haney, E., Nonhormonal therapies for menopausal hot flashes: Systematic review and meta-analysis (2006) JAMA, 295, pp. 2057-2071Stearns, V., Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms (2006) Treat Endocrinol, 5, pp. 83-87Muttukrishna, S., Child, T., Lockwood, G.M., Groome, N.P., Barlow, D.H., Ledger, W.L., Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women (2000) Hum Reprod, 15, pp. 549-556Burger, H.G., Dudley, E.C., Robertson, D.M., Dennerstein, L., Hormonal changes in the menopause transition (2002) Recent Prog Horm Res, 57, pp. 257-275Burger, H.G., Hale, G.E., Robertson, D.M., Dennerstein, L., A review of hormonal changes during the menopausal transition: Focus on findings from the Melbourne Women's Midlife Health Project (2007) Hum Reprod Update, 13, pp. 559-565Randolph Jr, J.F., Sowers, M., Gold, E.B., Reproductive hormones in the early menopausal transition: Relationship to ethnicity, body size, and menopausal status (2003) J Clin Endocrinol Metab, 88, pp. 1516-1522Randolph JF Jr, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 2004;89:1555-1561Aloysi, A., Van Dyk, K., Sano, M., Women's cognitive and affective health and neuropsychiatry (2006) Mt Sinai J Med, 73, pp. 967-975Elsabagh, S., Hartley, D.E., File, S.E., Cognitive function in late versus early postmenopausal stage (2007) Maturitas, 56, pp. 84-93Craig, M.C., Murphy, D.G., Oestrogen, cognition and the maturing female brain (2007) J Neuroendocrinol, 19, pp. 1-6Genazzani, A.R., Pluchino, N., Luisi, S., Luisi, M., Estrogen, cognition and female ageing (2007) Hum Reprod Update, 13, pp. 175-187Bottino CMC, Cid CG, Camargo CHP. Avaliação Neuropsicolo gica. In: Forlenza OV, Almeida OP eds. Depressão e Demência no Idoso-Tratamento Psicolo gico e Farmacologico. São Paulo: Lemos Editorial, 1997:121-140McArthur, J.C., Haughey, N., Gartner, S., Human immunodeficiency virus-associated dementia: An evolving disease (2003) J Neurovirol, 9, pp. 205-221Vázquez-Justo, E., Rodríguez-Alvarez, M., Influence of factors not related with HIV infection on neuropsychological performance of HIV-seropositive patients (2002) Rev Neurol, 35, pp. 474-480Casanova-Sotolongo, P., Casanova-Carrillo, P., Casanova-Carrillo, C., Dementia associated with AIDS (2002) Rev Neurol, 34, pp. 781-787Morrison, M.F., Petitto, J.M., Ten Have, T., Depressive and anxiety disorders in women with HIV infection (2002) Am J Psychiatry, 159, pp. 789-796Cook, J.A., Cohen, M.H., Burke, J., Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women (2002) J Acquir Immune Defic Syndr, 30, pp. 401-409Moore, J., Schuman, P., Schoenbaum, E., Boland, B., Solomon, L., Smith, D., Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America (1999) AIDS, 13, pp. 2459-2468Mello, V.A., Malbergier, A., Depression in women infected with HIV (2006) Rev Bras Psiquiatr, 28, pp. 10-17Ickovics, J.R., Hamburger, M.E., Vlahov, D., HIV Epidemiology Research Study Group. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: Longitudinal analysis from the HIV Epidemiology Research Study (2001) JAMA, 285, pp. 1466-1474Woods SP, Carey CL, Moran LM, Dawson MS, Letendre SL. Grant IHIV Neurobehavioral Research Center (HNRC) Group. Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Arch Clin Neuropsychol 2007;22:187-195Rabkin, J.G., Ferrando, S.J., van Gorp, W., Rieppi, R., McElhiney, M., Sewell, M., Relationships among apathy, depression, and cognitive impairment in HIV/AIDS (2000) J Neuropsychiatry Clin Neurosci, 12, pp. 451-457Ammassari, A., Antinori, A., Aloisi, M.S., Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons (2004) Psychosomatics, 45, pp. 394-402Starace, F., Bartoli, L., Aloisi, M.S., Cognitive and affective disorders associated to HIV infection in the HAART era: Findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study (2002) Acta Psychiatr Scand, 106, pp. 20-26De Ronchi, D., Faranca, I., Berardi, D., Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors (2002) Arch Neurol, 59, pp. 812-818McArthur, J.C., Brew, B.J., Nath, A., Neurological complications of HIV infection (2005) Lancet Neurol, 4, pp. 543-555McArthur, J.C., McDermott, M.P., McClernon, D., Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy (2004) Arch Neurol, 61, pp. 1687-1696Valcour, V.G., Shikuma, C.M., Watters, M.R., Sacktor, N.C., Cognitive impairment in older HIV-1-seropositive individuals: Prevalence and potential mechanisms (2004) AIDS, 18 (SUPPL. 1), pp. S79-S86McArthur, J.C., HIV dementia: An evolving disease (2004) J Neuroimmunol, 157, pp. 3-10Valcour, V., Paul, R., HIV infection and dementia in older adults (2006) Clin Infect Dis, 42, pp. 1449-1454Dore, G.J., McDonald, A., Li, Y., Kaldor, J.M., Brew, B.J., National HIV Surveillance Committee. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy (2003) AIDS, 17, pp. 1539-1545Robertson, K.R., Smurzynski, M., Parsons, T.D., The prevalence and incidence of neurocognitive impairment in the HAART era (2007) AIDS, 21, pp. 1915-1921McCutchan, J.A., Wu, J.W., Robertson, K., HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients (2007) AIDS, 21, pp. 1109-1117Schifitto, G., Kieburtz, K., McDermott, M.P., Clinical trials in HIV-associated cognitive impairment: Cognitive and functional outcomes (2001) Neurology, 56, pp. 415-418Sacktor, N., McDermott, M.P., Marder, K., HIV-associated cognitive impairment before and after the advent of combination therapy (2002) J Neurovirol, 8, pp. 136-142Wojna, V., Skolasky, R.L., Hechavarria, R., Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment (2006) J Neurovirol, 12, pp. 356-364Pandya, R., Krentz, H.B., Gill, M.J., Power, C., HIV-related neurological syndromes reduce health-related quality of life (2005) Can J Neurol Sci, 32, pp. 201-204Osowiecki, D.M., Cohen, R.A., Morrow, K.M., Neurocognitive and psychological contributions to quality of life in HIV-1-infected women (2000) AIDS, 14, pp. 1327-1332Heaton, R.K., Marcotte, T.D., Mindt, M.R., The impact of HIV-associated neuropsychological impairment on everyday functioning (2004) J Int Neuropsychol Soc, 10, pp. 317-331Cohen, R.A., Boland, R., Paul, R., Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women (2001) AIDS, 15, pp. 341-345Fillit, H.M., Butler, R.N., O'Connell, A.W., Achieving and maintaining cognitive vitality with aging (2002) Mayo Clin Proc, 77, pp. 681-696Raz, N., Rodrigue, K.M., Differential aging of the brain: Patterns, cognitive correlates and modifiers (2006) Neurosci Biobehav Rev, 30, pp. 730-748Prior, J., Burdge, D., Maan, E., Fragility fractures and bone mineral density in HIV positive women: A case-control population-based study (2007) Osteoporos Int, 18, pp. 1345-1353Siris, E.S., Miller, P.D., Barrett-Connor, E., Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment (2001) JAMA, 286, pp. 2815-2822Costa-Paiva, L., Horovitz, A.P., Santos, A.O., Fonsechi-Carvasan, G.A., Pinto-Neto, A.M., Prevalence of osteoporosis in postmenopausal women and association with clinical and reproductive factors (2003) Rev Bras Ginecol Obstet, 25, pp. 507-512Shilbayeh, S., Prevalence of osteoporosis and its reproductive risk factors among Jordanian women: A cross-sectional study (2003) Osteoporos Int, 14, pp. 929-940Yang, T.S., Chen, Y.R., Chen, Y.J., Chang, C.Y., Ng, H.T., Osteoporosis: Prevalence in Taiwanese women (2004) Osteoporos Int, 15, pp. 345-347Baheiraei, A., Pocock, N.A., Eisman, J.A., Nguyen, N.D., Nguyen, T.V., Bone mineral density, body mass index and cigarette smoking among Iranian women: Implications for prevention (2005) BMC Musculoskelet Disord, 6, p. 34NOF Patient info-medications to prevent and treat osteoporosis, , http://www.nof.org/patientinfo/medications.htm#Bone%20Remodeling%20Cycle, Available at:, Accessed December 20, 2007Amorosa, V., Tebas, P., Bone disease and HIV infection (2006) Clin Infect Dis, 42, pp. 108-114Fakruddin, J.M., Laurence, J., HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk (2003) J Biol Chem, 278, pp. 48251-48258Fakruddin, J.M., Laurence, J., HIV-1 Vpr enhances production of receptor of activated NF-κB ligand (RANKL) via potentiation of glucocorticoid receptor activity (2005) Arch Virol, 150, pp. 67-78Pan, G., Wu, X., McKenna, M.A., Feng, X., Nagy, T.R., McDonald, J.M., AZT enhances osteoclastogenesis and bone loss (2004) AIDS Res Hum Retroviruses, 20, pp. 608-620Wang, M.W., Teitelbaum, S.L., Tebas, P., Powderly, W.G., Ross, F.P., Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function (2001) Chicago, IL: 8th Conference on Retroviruses and Opportunistic Infections, , http://www.retroconference.org/2001/Abstracts/Abstracts/Abstracts/541.htm, abstract 541, Available at:, Accessed December 1, 2007Khosla S, Melton LJ 3rd, Atkinson EJ, Fallon O'WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83:2266-2274Bruera, D., Luna, N., David, D.O., Bergoglio, L.M., Zamudio, J., Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy (2003) AIDS, 17, pp. 1917-1923Brown, T.T., Qaqish, R.B., Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review (2006) AIDS, 20, pp. 2165-2174Van Rompay, K.K., Brignolo, L.L., Meyer, D.J., Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)-propyl]adenine (tenofovir) to newborn and infant rhesus macaques (2004) Antimicrob Agents Chemother, 48, pp. 1469-1487Nolan, D., Upton, R., McKinnon, E., Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir (2001) AIDS, 15, pp. 1275-1280Wang, M.W., Wei, S., Faccio, R., The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling (2004) J Clin Invest, 114, pp. 206-213Fakruddin, J.M., Yin, M., Laurence, J., Pathophysiologic correlates of RANKL deregulation in HIV infection and its therapy (2005) Boston, MA: 12th Conference on Retroviruses and Opportunistic Infections, , http://www.retroconference.org/2005/cd/Abstracts/24609.htm, abstract 822, Available at:, Accessed December 1, 2007Aukrust, P., Haug, C.J., Ueland, T., Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy (1999) J Clin Endocrinol Metab, 84, pp. 145-150Anastos, K., Lu, D., Shi, O., The association of bone mineral density with HIV infection and antiretroviral treatment in women (2007) Antivir Ther, 12, pp. 1049-1058Mondy, K., Powderly, W.G., Claxton, S.A., Alendronate, vitamin D, and calcium for the treatment of osteopenia-osteoporosis associated with HIV infection (2005) J Acquir Immune Defic Syndr, 38, pp. 426-431Negredo, E., Martinez-Lopez, E., Paredes, R., Reversal of HIV-1-associated osteoporosis with once-weekly alendronate (2005) AIDS, 19, pp. 343-345Guaraldi, G., Orlando, G., Madeddu, G., Alendronate reduces bone resorption in HIV-associated osteopenia-osteoporosis (2004) HIV Clin Trials, 5, pp. 269-277Lin, D., Rieder, M.J., Interventions for the treatment of decreased bone mineral density associated with HIV infection Cochrane Database Syst Rev, 2007 (2). , CD005645Negredo, E., Martinez, E., Cinquegrana, D., Estany, C., Clotet, B., Therapeutic management of bone demineralization in the HIV-infected population (2007) AIDS, 21, pp. 657-663Carr, A., Samaras, K., Burton, S., A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors (1998) AIDS, 12, pp. F51-F58Friis-Møller, N., Weber, R., Reiss, P., Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study (2003) AIDS, 17, pp. 1179-1193Mondy, K., Tebas, P., Cardiovascular risks of antiretroviral therapies (2007) Annu Rev Med, 58, pp. 141-155Gharakhanian, S., Salhi, Y., Nguyen, T.H., Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors (1999) Chicago, IL: 6th Conference on Retroviruses and Opportunistic Infections, , http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102195407.html, abstract 642, Available at:, Accessed August 13, 2008Hadigan, C., Miller, K., Corcoran, C., Anderson, E., Basgoz, N., Grinspoon, S., Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women (1999) J Clin Endocrinol Metab, 84, pp. 1932-1937Tien, P.C., Cole, S.R., Williams, C.M., Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study (2003) J Acquir Immune Defic Syndr, 34, pp. 461-466Gervasoni, C., Ridolfo, A.L., Trifiro, G., Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy (1999) AIDS, 13, pp. 465-471Puttawong, S., Prasithsirikul, W., Vadcharavivad, S., Prevalence of lipodystrophy in Thai-HIV infected patients (2004) J Med Assoc Thai, 87, pp. 605-611Dong, K.L., Bausserman, L.L., Flynn, M.M., Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART) (1999) J Acquir Immune Defic Syndr, 21, pp. 107-113Martinez, E., Mocroft, A., García-Viejo, M.A., Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study (2001) Lancet, 357, pp. 592-598Huang, J.S., Harrity, S., Lee, D., Becerra, K., Santos, R., Mathews, W.C., Body image in women with HIV: A cross-sectional evaluation (2006) AIDS Res Ther, 3, p. 17Mauss, S., Corzillius, M., Wolf, E., Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment (2002) HIV Med, 3, pp. 49-55Poehlman, E.T., Toth, M.J., Ades, P.A., Rosen, C.J., Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: A longitudinal study (1997) Eur J Clin Invest, 27, pp. 322-326Savès, M., Chêne, G., Ducimetière, P., Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population (2003) Clin Infect Dis, 37, pp. 292-298Matthews, K.A., Kuller, L.H., Sutton-Tyrrell, K., Chang, Y.F., Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women (2001) Stroke, 32, pp. 1104-1111Friis-Møller, N., Sabin, C.A., Weber, R., Combination antiretroviral therapy and the risk of myocardial infarction (2003) N Engl J Med, 349, pp. 1993-2003Friis-Møller, N., Reiss, P., Sabin, C.A., Class of antiretroviral drugs and the risk of myocardial infarction (2007) N Engl J Med, 356, pp. 1723-1735Torriani, F.J., Parker, R.A., Murphy, R.L., Antiretroviral therapy improves endothelial function in treatment-naïve HIV-infected subjects: A prospective, randomized multicenter trial [PS5/3]. Dublin (2005) Ireland: 10th European AIDS Conference, , http://www.eacs.eu/conference/dublin05/RES/214.html, Available at:, Accessed August 13, 2008Currier, J.S., Kendall, M.A., Zackin, R., Carotid artery intima-media thickness and HIV infection: Traditional risk factors overshadow impact of protease inhibitor exposure (2005) AIDS, 19, pp. 927-933Johnsen, S., Dolan, S.E., Fitch, K.V., Carotid intimal medial thickness in human immunodeficiency virus-infected women: Effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome (2006) J Clin Endocrinol Metab, 91, pp. 4916-4924Akahoshi, M., Soda, M., Nakashima, E., Shimaoka, K., Seto, S., Yano, K., Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index (1996) Circulation, 94, pp. 61-66Otsuki, M., Kasayama, S., Morita, S., Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women (2007) Menopause, 14, pp. 404-407Currier, J.S., Cardiovascular risk associated with HIV therapy (2002) J Acquir Immune Defic Syndr, 31 (SUPPL. 1), pp. S16-S23Collins, P., Rosano, G., Casey, C., Management of cardiovascular risk in the peri-menopausal woman: A consensus statement of European cardiologists and gynaecologists (2007) Eur Heart J, 28, pp. 2028-2040Carosi, G., Quiros-Roldan, E., Torti, C., First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) (2007) Infection, 35, pp. 134-142